LACEi or ARBs were dispensed in pregnancies with chronic hypertension (590/735, 80.3%), preeclampsia superimposed on chronic hypertension (130/735, 17.7%), and gestational hypertension (15/735, 2.0%). The utilization of ACEi or ARBs for therapy of HDP was low, but not absent.
We identified 105,277 women with threatened abortion (TA), with a median follow-up of 16.9 years (interquartile range 10.5-24.4 years). During the follow-up, 6,571 women with TA developed cancer. The standardised incidence ratio (SIR) for any cancer was 1.01 (95% CI=0.98-1.03). TA was not associated with an increased risk of cancer of breast (SIR=1.02, 95% CI=0.98-1.07), uterine cervix (SIR=0.93, 95% CI=0.83-1.03), ovary (SIR=0.91, 95% CI=0.78-1.06); or uterus (SIR=0.79, 95% CI=0.66-0.95). TA is not associated with an increased risk of cancer diagnosis.